OT-101 is being developed to treat the long-term effects of respiratory distress after Covid-19 infection. Credit: Fusion Medical Animation / Unsplash.

Oncotelic Therapeutics has received a contract from the US Biomedical Advanced Research and Development Authority (BARDA) to develop OT-101 to treat the long-term effects of respiratory distress after Covid-19 infection.

Under the contract, the company will collect long-term clinical data from patients with Covid-19 in Peru and Argentina, where the C001-2020-01 trial was carried out.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The data will show the therapy’s potential effectiveness for the treatment of the long-term effects of respiratory distress caused by Covid-19.

Oncotelic stated that the data would be used for designing the next clinical trial to demonstrate OT-101’s effectiveness against long-term Covid-19 as well as the disease.

Antisense against TGF-β2, OT-101 is also developed to treat solid tumours and patients with colorectal carcinoma, pancreatic carcinoma, malignant melanoma, high-grade glioma (HGG), as well as other TGF-β2 overexpressing malignancies.

It has already completed seven clinical trials, which include two Phase II trials in brain cancer and pancreatic cancer and one Phase II randomised, double-blind, placebo-controlled trial in Covid-19 in South America.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company noted that OT-101 also holds a paediatric designation to treat a rare form of paediatric brain cancer, which is known as DIPG.

The Administration for Strategic Preparedness and Response; Department of Health and Human Services; and Biomedical Advanced Research and Development Authority provided funding for the project in whole or part with federal funds.

In November last year, Oncotelic reported that OT-101 met the safety and efficacy endpoints of the Phase II C001 clinical trial, which was conducted in severe Covid-19 patients admitted to the hospital.